Shares surged 10% to $88.80 in after-hours trading after TransMedics, the company behind portable organ-preservation systems used in transplant surgery, posted record quarterly revenue and raised its full-year outlook. The question facing investors: is rapid top-line growth worth the steep erosion in profits?
Record Revenue, but Earnings Cut in Half
Revenue hit $189.9 million in Q2, up 20.7% from $157.4 million a year earlier.
Product revenue rose 16% to $111.2 million while service revenue — logistics and clinical support — jumped 29% to $78.8 million. Yet net income collapsed 57.9% to $14.7 million, and diluted EPS fell from $0.92 to $0.41.
Adjusted EPS of $0.44 missed analyst estimates of roughly $0.53 by about 16%. Wall Street cheered the revenue beat but the earnings miss is a clear warning: growth is being bought with margin.
The Spending Bet Behind the Margin Drop
Adjusted operating margin contracted sharply to 13.6% from 23.2% a year ago — a nearly 10-percentage-point decline.
A channel shift toward recurring service revenue expanded the logistics footprint but dragged down gross margins. Management is pouring cash into next-generation organ systems, a kidney program not expected to reach clinics until 2027, and clinical trials for heart and lung devices. The company targets a 30% operating margin by 2028 — nearly triple today's rate. That's a bold promise that hinges on volume scaling faster than costs.
Guidance Raise Signals Confidence — With Caveats
TransMedics raised the low end of its 2026 revenue guidance from $727 million to $737 million, creating a new range of $737–$757 million (roughly 22–25% growth), excluding a recent European aviation investment.
However, management cautioned that Q3 could be seasonally soft, noting July's strong performance may not hold through August and September.
Cash Cushion Buys Time, But Not Indefinitely
TransMedics held $472.7 million in cash at quarter-end , giving it ample runway. International revenue remains small at roughly $5 million per quarter, the kidney program is years from commercialization, and key regulatory decisions — including whether TransMedics can become an organ procurement organization — remain outside management's control. Investors buying today are betting that a dominant position in transplant logistics justifies years of compressed profits. The revenue trajectory supports that thesis; the margin math still needs to prove it.